Can Covaxin booster dose prolong protection?
In a meeting held on March 24, the Subject Expert Committee of the India drug regulator permitted Bharat Biotech to
Read More
How can India contain the COVID-19 second wave?
When do you think the second wave is likely to peak? And when we see such a peak, what do
Read More
In a major shift, India fast-tracks restricted use approval for COVID-19 vaccines developed in other countries
The vaccines that would be eligible for the fast-track approval will include those that have been granted an EUA by
Read More
COVID-19: Protection against reinfection may last only for months
The first serosurvey was carried out in August-September 2020 and the six-month follow-up was carried out in end-January to February
Read More
India will add four million more COVID-19 cases by May 1, says Giridhara Babu
The increase in daily cases has been very steep — from over 12,200 cases on March 1 to over 1,26,000
Read More
180 deaths following COVID-19 vaccination reported in India
In all, 492 severe and serious AEFI have been classified by the AEFI Secretariat of the immunisation technical support unit
Read More
Health Ministry reveals the names of SEC members for COVID-19 vaccine approval
Names of members Dr. Varsha Gupta, Professor, Department of Microbiology, Government Medical College Hospital, Chandigarh; 2) Dr. Archana Thakur, Medical
Read More
What is driving COVID-19 second wave in India?
The rate of increase in cases in India during March has been faster than at any other time during the
Read More
Covaxin: SEC allows Bharat Biotech to unblind all participants above 45 years
The Subject Expert Committee has permitted Bharat Biotech to unblind all phase-3 trial participants above 45 years and offer the vaccine to those who received a placebo. The reason: vaccines (including Covaxin) are already available under the immunisation programme, and therefore all the eligible age groups should be unblinded for vaccination.
Read More
Will intranasal COVID-19 vaccines confer sterilising immunity?
Developed by Washington University School of Medicine in St. Louis, the vaccine has been licensed to Bharat Biotech to carry
Read More
Achieving COVID-19 vaccine equity by making comorbidities redundant for those above 45 years
By following the U.K. model of vaccinating people based on age bands rather than focussing on comorbidities, millions of people
Read More
Should Covaxin trial continue till 130 cases are recorded?
According to details posted on the clinical trial registry, the company had planned to “continue the phase-3 trial until 130
Read More
Will adenovirus antibodies reduce the efficacy of COVID-19 vector vaccines?
While it is unclear if pre-existing antibodies to adenovirus vector will affect vaccine efficacy, it is possible that repeated vaccination using adenovirus-based vaccine either as a booster or as annual vaccination, if the need arises, will result in reduced efficacy due to vector immunity.
Read More